Positive results for UBC® Rapid in an Austrian study | IDL Biotech
IDL Biotech

CLOSE MENU

Articles

Latest News

August 2017

Positive results for UBC® Rapid in an Austrian study

International Journal of Medical Sciences has published an Austrian study with UBC® Rapid performed at the Department of Urology, Medical University of Innsbruck. Urinary samples were analyzed by cytology, UBC® Rapid and NMP22 BladderChek® test.

The results from this study coincide very well with the results from previous reported studies, with a very high UBC® Rapid sensitivity for in particular high grade bladder cancer tumors compared to both cytology and NMP22 BladderChek® test.

Bladder cancer is a common and resource-intensive cancer. Patients often need extensive and long-term follow-up after primary diagnosis. Methods for early detection and regular follow-up are of great importance.

Cystoscopy, a procedure in which the inside of the bladder is examined using an optical instrument, is the most commonly used method for detection of bladder cancer.

The use of urine-based markers in evaluation of bladder cancer is an interesting approach since the tumors are constantly in contact with urine. UBC® Rapid is a non-invasive test detecting cytokeratin 8 and 18 fragments released from urothelial cells into the urine as markers for bladder cancer. UBC® Rapid combined with a reader is the first quantitative point-of-care system for bladder cancer, enabling risk stratification in a point-of-care setting.

Annual meeting/Årsstämma

Årsstämma hålls den 27 maj 2020 kl. 15.00 på Piperska Muren, Scheelegatan 14, 112 28 Stockholm.

IDL Biotech signs new distribution agreement with Beckman Coulter, which gives the distributor global sales rights for the company's tumor markers on the ELISA manual platform.

Beckman Coulter has been one of IDL Biotech's most successful tumor markers distributors, and has sold the products in the Czech Republic and Slovakia for many years. With Beckman Coulter now taking over the global distribution rights for the company's tumor markers, we can intensify our focus on rapid testing and automation. At the same time, it gives Beckman Coulter the opportunity to broaden his product portfolio within tumor markers, ”says Charlotte Berg, CEO of IDL Biotech. IDL Biotech will continue to produce the tumor markers. The agreement is global, excluding the Chinese market.

IDL Biotech

Skip this intro